The U.S. Food and Drug Administration is taking North Chicago-based drugmaker AbbVie to task, warning in a recent letter that a migraine medication commercial featuring Serena Williams is “misleading.

Office of Prescription Drug Promotion (OPDP) recently sent an Untitled Letter to AbbVie, Inc., regarding a television ad starring Serena Williams for its migraine medicine Ubrelvy. According to the ...

The regulator said it withdrew authorisation for the drug on Sept. 25. It added that the authorisation holder, listed as ...

The insurers are looking to disrupt Big Pharma's model of distributing drugs. One of them's even offering to give them to ...

“We are actively addressing the FDA enforcement action regarding the TV commercial referenced in the letter, which stopped airing in the first half of this year,” a spokesperson for AbbVie ...

AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this ...

Sept 10 (Reuters) - UnitedHealth Group (UNH.N), opens new tab said on Tuesday it will remove AbbVie’s (ABBV.N ... biosimilars covered on its lists for commercial health plans, which are ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

The U.S. Food and Drug Administration is taking North Chicago-based drugmaker AbbVie to task, warning in a recent letter that a migraine medication commercial featuring Serena Williams is ...